An open-label, two-period, fixed sequence, randomized, parallel group, interaction study to determine the effects of repeat doses of relacatib on the metabolism of acetaminophen [paracetamol], ibuprofen and atorvastatin in healthy postmenopausal female subjects.

Trial Profile

An open-label, two-period, fixed sequence, randomized, parallel group, interaction study to determine the effects of repeat doses of relacatib on the metabolism of acetaminophen [paracetamol], ibuprofen and atorvastatin in healthy postmenopausal female subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2009

At a glance

  • Drugs Relacatib (Primary) ; Atorvastatin; Ibuprofen; Paracetamol
  • Indications Osteoarthritis; Osteoporosis
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Apr 2008 Status changed from in progress to completed.
    • 03 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top